Additional Study Information: This study is being done to obtain information on the safety and side effects, good or bad, of two new drug combinations; AMG 510 plus trametinib and AMG 510 plus AMG 404. Subjects will participate in one of two research groups. Group A will receive AMG 510 and trametinib. Research Group B will receive AMG 510 and AMG 404. AMG 510 is an anticancer drug that is being developed for tumors with a specific mutation called KRAS p.G12C. AMG 404 is an anticancer drug that works by activating an immune response against the cancer by blocking the activity of a molecule called PD-1. Trametinib is an anticancer drug that interferes with the growth and spread of cancer cells in the body.